Docket #0964 Date Filed: 11/04/2026

UNITED STATES BANKRUPTCY COURT

Northern DISTRICT OF Texas

Dallas Division

In re: EIGER BIOPHARMACEUTICALS, INC., et al. § Case No. 24-80040

§

§

Debtor(s) §

☐ Jointly Administered

Post-confirmation Report

Chapter 11

Quarter Ending Date: 09/30/2026 Petition Date: 04/01/2024

Plan Confirmed Date: 09/05/2024 Plan Effective Date: 09/30/2024

This Post-confirmation Report relates to:

○ Reorganized Debtor

◉ Other Authorized Party or Entity: Liquidating Trust for Eiger BioPhamaceut

Name of Authorized Party or Entity

/s/ Margie Venus

Signature of Responsible Party

11/4/2026

Date

Margie Venus

Printed Name of Responsible Party

600 Travis Street, Suite 7000
Houston, Texas, 77002

Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.

2480040261104000000000006

Debtor's Name EIGER BIOPHARMACEUTICALS, INC., et al. Case No. 24-80040

Part 1: Summary of Post-confirmation Transfers

	Current Quarter	Total Since Effective Date
a. Total cash disbursements	$245,153	$13,992,727
b. Non-cash securities transferred	$0	$0
c. Other non-cash property transferred	$0	$0
d. Total transferred (a+b+c)	$245,153	$13,992,727

Part 2: Preconfirmation Professional Fees and Expenses

				Approved Current	Approved Cumulative	Paid Current Quarter	Paid Cumulative
a.	Professional fees & expenses (bankruptcy) incurred by or on behalf of the debtor		*Aggregate Total*	$0	$14,404,360	$0	$14,404,360
	Itemized Breakdown by Firm						
		Firm Name	Role				
	i	Alvarez & Marsal	Financial Professional	$0	$3,452,114	$0	$3,452,114
	ii	KCC, LCC	Other	$0	$953,110	$0	$953,110
	iii	Sidley Austin LLP	Lead Counsel	$0	$8,331,110	$0	$8,331,110
	iv	SSG Advisors, LLC	Other	$0	$155,031	$0	$155,031
	v	Porzio, Bromberg & Newm	Co-Counsel	$0	$978,267	$0	$978,267
	vi	McKool Smith PC	Co-Counsel	$0	$452,130	$0	$452,130
	vii	Dundon Advisers LLC	Financial Professional	$0	$82,598	$0	$82,598
	viii						
	ix						
	x						
	xi						
	xii						
	xiii						
	xiv						
	xv						
	xvi						
	xvii						
	xviii						
	xix						
	xx						
	xxi						
	xxii						
	xxiii						
	xxiv						
	xxv						
	xxvi						
	xxvii						
	xxviii						
	xxix						

Debtor's Name EIGER BIOPHARMACEUTICALS, INC., et al. Case No. 24-80040

	xxx						
	xxxi						
	xxxii						
	xxxiii						
	xxxiv						
	xxxv						
	xxxvi						
	xxxvii						
	xxxviii						
	xxxix						
	xl						
	xli						
	xlii						
	xliii						
	xliv						
	xlv						
	xlvi						
	xlvii						
	xlviii						
	xlix						
	l						
	li						
	lii						
	liii						
	liv						
	lv						
	lvi						
	lvii						
	lviii						
	lix						
	lx						
	lxi						
	lxii						
	lxiii						
	lxiv						
	lxv						
	lxvi						
	lxvii						
	lxviii						
	lxix						
	lxx						
	lxxi						

Debtor's Name EIGER BIOPHARMACEUTICALS, INC., et al. Case No. 24-80040

	lxxii						
	lxxiii						
	lxxiv						
	lxxv						
	lxxvi						
	lxxvii						
	lxxviii						
	lxxix						
	lxxx						
	lxxxi						
	lxxxii						
	lxxxiii						
	lxxxiv						
	lxxxv						
	lxxxvi						
	lxxxvii						
	lxxxvii						
	lxxxix						
	xc						
	xci						
	xcii						
	xciii						
	xciv						
	xcv						
	xcvi						
	xcvii						
	xcviii						
	xcix						
	c						
	ci						

b.				Approved Current	Approved Cumulative	Paid Current Quarter	Paid Cumulative
	Professional fees & expenses (nonbankruptcy) incurred by or on behalf of the debtor *Aggregate Total*						
	Itemized Breakdown by Firm						
		Firm Name	Role				
	i						
	ii						
	iii						
	iv						
	v						
	vi						

Debtor's Name EIGER BIOPHARMACEUTICALS, INC., et al. Case No. 24-80040

	vii						
	viii						
	ix						
	x						
	xi						
	xii						
	xiii						
	xiv						
	xv						
	xvi						
	xvii						
	xviii						
	xix						
	xx						
	xxi						
	xxii						
	xxiii						
	xxiv						
	xxv						
	xxvi						
	xxvii						
	xxviii						
	xxix						
	xxx						
	xxxi						
	xxxii						
	xxxiii						
	xxxiv						
	xxxv						
	xxxvi						
	xxxvii						
	xxxviii						
	xxxix						
	xl						
	xli						
	xlii						
	xliii						
	xliv						
	xlv						
	xlvi						
	xlvii						
	xlviii						

Debtor's Name EIGER BIOPHARMACEUTICALS, INC., et al. Case No. 24-80040

	xlix						
	l						
	li						
	lii						
	liii						
	liv						
	lv						
	lvi						
	lvii						
	lviii						
	lix						
	lx						
	lxi						
	lxii						
	lxiii						
	lxiv						
	lxv						
	lxvi						
	lxvii						
	lxviii						
	lxix						
	lxx						
	lxxi						
	lxxii						
	lxxiii						
	lxxiv						
	lxxv						
	lxxvi						
	lxxvii						
	lxxviii						
	lxxix						
	lxxx						
	lxxxi						
	lxxxii						
	lxxxiii						
	lxxxiv						
	lxxxv						
	lxxxvi						
	lxxxvii						
	lxxxvii						
	lxxxix						
	xc						

Debtor's Name EIGER BIOPHARMACEUTICALS, INC., et al. Case No. 24-80040

	xci						
	xcii						
	xciii						
	xciv						
	xcv						
	xcvi						
	xcvii						
	xcviii						
	xcix						
	c						
	ci						
c.	All professional fees and expenses (debtor & committees)						

Part 3: Recoveries of the Holders of Claims and Interests under Confirmed Plan

	Total Anticipated Payments Under Plan	Paid Current Quarter	Paid Cumulative	Allowed Claims	% Paid of Allowed Claims
a. Administrative claims	$0	$0	$0	$0	0%
b. Secured claims	$0	$0	$0	$0	0%
c. Priority claims	$276,440	$0	$197,372	$276,440	71%
d. General unsecured claims	$3,760,715	$0	$3,636,753	$3,760,715	97%
e. Equity interests	$6,736,437	$0	$5,750,000		

Part 4: Questionnaire

a. Is this a final report? Yes ○ No ◉

If yes, give date Final Decree was entered: _____

If no, give date when the application for Final Decree is anticipated: _____

b. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930? Yes ◉ No ○

Debtor's Name EIGER BIOPHARMACEUTICALS, INC., et al. Case No. 24-80040

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information and provision of this information is mandatory. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6) and to otherwise evaluate whether a reorganized chapter 11 debtor is performing as anticipated under a confirmed plan. Disclosure of this information may be to a bankruptcy trustee when the information is needed to perform the trustee's duties, or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." *See* 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case, or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Post-confirmation Report and its attachments, if any, are true and correct and that I have been authorized to sign this report.


/s/ Joshua Nahas
Signature of Responsible Party

Joshua Nahas
Printed Name of Responsible Party


Liquidating Trustee
Title

11/4/2026
Date


Debtor's Name EIGER BIOPHARMACEUTICALS, INC., et al. Case No. 24-80040




Page 1



Other Page 1




Page 2 Minus Tables




Bankruptcy Table 1-50


Debtor's Name EIGER BIOPHARMACEUTICALS, INC., et al. Case No. 24-80040




Bankruptcy Table 51-100



Non-Bankruptcy Table 1-50



Non-Bankruptcy Table 51-100



Part 3, Part 4, Last Page

ADDENDUM

General. On September 30, 2024, Eiger BioPharmaceuticals Inc., et al., distributed $12,300,000 to the Eiger BioPharmaceuticals Inc., et al. Liquidating Trust (the "Initial Funding"), and on October 23, 2024 and October 24, 2024, Eiger InnoTherapeutics Inc. distributed $1,450,000 (collectively, the "Trust Assets") in accordance with the Debtors' confirmed chapter 11 plan. As the estate has already paid U.S. Trustee fees on the $12,300,000 of Trust Assets as they entered the Eiger BioPharmaceuticals Inc., et al. Liquidating Trust, it need not pay U.S. Trustee fees again when those same Trust Assets are distributed to creditors under the Plan.

Part 3(d) and Part 3(e). The Liquidating Trustee has made payment thus far for $3,636,753.01 to the General Unsecured Creditors, $197,372 to the Priority Claims, and $5,750,000 to Equity Interests. Cumulative Trust disbursements through September 30, 2026 total $9,584,125.01, which is below the $12,300,000 Initial Funding. The Trust therefore owes no quarterly fee on these disbursements at this time. Once cumulative disbursements exceed the Initial Funding, the Trust will include its disbursements in the quarterly fee calculation again.